我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
隶属于 Apotex, Inc.
相关临床试验
0
0 进行中
药物批准
345
批准总数
监管机构
1
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
FDA
Food and Drug Administration
- Apotex Corp. announced the launch of nilotinib capsules, the first generic version of Tasigna® in the United States, with 180 days of market exclusivity. - The kinase inhibitor is indicated for treating Philadelphia chromosome positive chronic myeloid leukemia in adults and children aged 1 year and older. - The generic launch aims to improve patient access to this critical leukemia treatment by providing a more affordable alternative to the brand-name medication. - Nilotinib demonstrates higher efficacy compared with other available treatments for patients with resistance or intolerance to prior therapy.
